ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)
ISSN 2383-9457 (ONLINE)
Incremental socioeconomic benefits of trastuzumab-deruxtecan that come along with the improved progression free survival
| Age group | No. of patients | Median PFS of T-DM1 (month) | Median PFS of T-DXd (month) | Paid work | Unpaid work | Total incremental benefits (KRW) | Incremental benefits per patient (KRW) | ||
|---|---|---|---|---|---|---|---|---|---|
| Hours gained | Incremental benefits (KRW) | Hours gained | Incremental benefits (KRW) | ||||||
| 20-29 | 97 | 11.1 | 36.5 | 086,664 | 04,067,456,883 | 166,602 | 07,819,238,949 | 11,886,695,832 | 122,543,256 |
| 30-39 | 422 | 12.5 | 41.1 | 446,120 | 20,938,022,830 | 816,119 | 38,303,416,966 | 59,241,439,796 | 140,382,559 |
| 40-49 | 836 | 10.4 | 34.2 | 773,415 | 36,299,139,148 | 1,345,4220 | 63,145,479,957 | 99,444,619,105 | 118,952,894 |
| 50-59 | 623 | 10.2 | 33.6 | 563,197 | 26,432,875,192 | 985,778 | 46,266,104,897 | 72,698,980,089 | 116,691,782 |
| 60-64 | 115 | 8.8 | 29.1 | 068,337 | 03,207,309,464 | 157,859 | 07,408,886,000 | 10,616,195,464 | 092,314,743 |
| 65+ | 119 | 7.1 | 23.4 | 029,836 | 01,400,295,739 | 131,163 | 06,155,928,967 | 07,556,224,706 | 063,497,687 |
| Total | 2,212 | 92,345,099,257 | 169,099,055,7360 | 261,444,154,9920 | 118,193,560 | ||||
Abbreviations: T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan; PFS, progression-free survival; KRW, Korean won.